{
  "ticker": "MAP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960999",
  "id": "02960999",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1235",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0dkhmfkk60n.pdf",
  "summary": "### **Summary of ASX Announcement \u2013 MAP (Microba Life Sciences Limited)**  \n**Announcement Type:** *Proposed Issue of Securities (Options)*  \n\n- **Security Type:** Options (New class)  \n- **Underlying Security:** MAP Ordinary Shares  \n- **Options to be Issued:** 46,222,222  \n- **Exercise Price:** AUD 0.090 per share  \n- **Expiry Date:** 13-Jan-2027  \n- **Issue Date (Proposed):** 13-Aug-2025  \n- **Attaching Options:**  \n  - **Ratio:** 1 attaching option per 4 shares issued (max ~11.56M options).  \n  - **Terms:** Exercise price AUD 0.108, expiry 36 months post-issue.  \n- **Conditions:**  \n  - Shareholder approval required (meeting scheduled for 8-Aug-2025).  \n- **Purpose of Issue:** Fund commercialization of MetaXplore/MetaPanel (R&D, sales/marketing in AU/UK, working capital).  \n- **Key Risks/Omissions:** No underwriting, lead manager, or escrow. No change to dividend policy.  \n\n*Note: Zero cash consideration (options issued as part of strategic agreement with Sonic Healthcare).*  \n\n**Trading Implication:** Dilution risk (~46.2M shares if fully exercised, plus ~11.6M attaching options). Monitor shareholder vote outcome (8-Aug-2025).",
  "usage": {
    "prompt_tokens": 1860,
    "completion_tokens": 307,
    "total_tokens": 2167,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T03:21:15.985733"
}